Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/108816
Title: Associations between gender, disease features and symptom burden in the MPN population: An analysis by the MPN QOL International Working Group
Author: Geyer, Holly L.
Kosiorek, Heidi
Dueck, Amylou C.
Scherber, Robyn
Slot, Stefanie
Zweegman, Sonja
Te Boekhorst, Peter A.
Senyak, Zhenya
Schouten, Harry C.
Sackmann, Federico
Kerguelen Fuentes, Ana
Hernández-Maraver, Dolores
Pahl, Heike L.
Griesshammer, Martin
Stegelmann, Frank
Döhner, Konstanze
Lehmann, Thomas
Bonatz, Karin
Reiter, Andreas
Boyer, Francoise
Etienne, Gabriel
Ianotto, Jean-Christophe
Ranta, Dana
Roy, Lydia
Cahn, Jean-Yves
Harrison, Claire N.
Radia, Deepti
Muxi, Pablo
Maldonado, Norman
Besses, Carlos
Cervantes Requena, F.
Johansson, Peter L.
Barbui, Tiziano
Barosi, Giovanni
Vannucchi, Alessandro M.
Paoli, Chiara
Passamonti, Francesco
Andreasson, Bjorn
Ferrari, Maria L.
Rambaldi, Alessandro
Samuelsson, Jan
Cannon, Keith
Birgegard, Gunnar
Xiao, Zhijian
Xu, Zefeng
Zhang, Yue
Sun, Xiujuan
Xu, Junqing
Kiladjian, Jean-Jacques
Zhang, Peihong
Gale, Robert Peter
Mesa, Ruben A.
Keywords: Factors sexuals en les malalties
Trastorns de les plaquetes sanguínies
Mielomatosi
Sex factors in disease
Blood platelet disorders
Myeloproliferative disorders
Issue Date: 1-Jan-2017
Publisher: Ferrata Storti Foundation
Abstract: The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications and profound impact on quality of life. The role gender plays in the symptomatology of myeloproliferative neoplasms remains under-investigated. In this study we evaluated how gender relates to patients' characteristics, disease complications and overall symptom expression. A total of 2,006 patients (polycythemia vera=711, essential thrombocythemia=830, myelofibrosis=460, unknown=5) were prospectively evaluated, with patients completing the Myeloproliferative Neoplasm-Symptom Assessment Form and Brief Fatigue Inventory Patient Reported Outcome tools. Information on the individual patients' characteristics, disease complications and laboratory data was collected. Consistent with known literature, most female patients were more likely to have essential thrombocythemia (48.6% versus 33.0%; P<0.001) and most male patients were more likely to have polycythemia vera (41.8% versus 30.3%; P<0.001). The rate of thrombocytopenia was higher among males than females (13.9% versus 8.2%; P<0.001) and males also had greater red-blood cell transfusion requirements (7.3% versus 4.9%; P=0.02) with shorter mean disease duration (6.4 versus 7.2 years, P=0.03). Despite there being no statistical differences in risk scores, receipt of most therapies or prior complications (hemorrhage, thrombosis), females had more severe and more frequent symptoms for most individual symptoms, along with overall total symptom score (22.8 versus 20.3; P<0.001). Females had particularly high scores for abdominal-related symptoms (abdominal pain/discomfort) and microvascular symptoms (headache, fatigue, insomnia, concentration difficulties, dizziness; all P<0.01). Despite complaining of more severe symptom burden, females had similar quality of life scores to those of males. The results of this study suggest that gender contributes to the heterogeneity of myeloproliferative neoplasms by influencing phenotypic profiles and symptom expression.
Note: Reproducció del document publicat a: https://doi.org/10.3324/haematol.2016.149559
It is part of: Haematologica, 2017, vol. 102, num. 1, p. 85-93
Related resource: https://doi.org/10.3324/haematol.2016.149559
URI: http://hdl.handle.net/2445/108816
ISSN: 0390-6078
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
669560.pdf485.73 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.